Press Releases

Date	Title	PDF Version
Sep 13, 2016	Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases
Sep 06, 2016	Alexion to Present at Upcoming Investor Conferences
Aug 29, 2016	European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
Jul 28, 2016	Alexion Reports Second Quarter 2016 Results
Jul 14, 2016	Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
Jul 11, 2016	Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016
Jul 07, 2016	New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress
Jun 10, 2016	Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
Jun 06, 2016	Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
Jun 01, 2016	European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Search